



PRESS RELEASE

20th July 2023

APIS Assay Technologies Ltd. Announces Appointment of New CEO and Executive Chairman of the Board

Today, the board of directors (“Board”) for APIS Assay Technologies Ltd (“APIS”) has agreed to changes to the executive management team.

Dr Ian Kavanagh, following a nearly 5-year tenure as APIS’s Chief Operating Officer (COO), has been appointed the Chief Executive Officer (CEO).

Dr Joachim Schorr, who has been APIS’s Chief Executive Officer since September 2018, will move into a new role as Executive Chairman of the Board.

Dr Schorr founded APIS in September 2018 with the support of Manchester City Council and QIAGEN. As part of the executive restructure, it was agreed that the current COO, Ian Kavanagh be appointed as new CEO, effective from July 18th, 2023. Dr Kavanagh will lead the development and execution of short- and long-term strategies that drive revenue growth and profitability while ensuring that APIS remains true to its mission and values.

As the Executive Chair, Dr Schorr will be an executive director of APIS, responsible for leading the Board and ensuring that it fulfils its governance responsibilities. In his new role, Dr Schorr will also focus on investment opportunities to support the growth of the company.

“This executive restructuring will enable APIS to continue its path to advancing precision medicine with next-generation molecular diagnostics and therapeutics,” said Dr Schorr.

Dr Schorr also expressed an enormous gratitude to Rowena Burns, who has served as the Chair of the Board for the last five years. Rowena has been essential to the development of APIS with her continued support and network. Rowena Burn will remain as a non-executive director of the Board.